Zobrazeno 1 - 10
of 462
pro vyhledávání: '"Dan G, Duda"'
Autor:
Shadi Chamseddine, Betul Gok Yavuz, Yehia I. Mohamed, Sunyoung S. Lee, James C. Yao, Zishuo Ian Hu, Michael LaPelusa, Lianchun Xiao, Ryan Sun, Jeffrey S. Morris, Rikita I. Hatia, Manal Hassan, Dan G. Duda, Maria Diab, Amr Mohamed, Ahmed Nassar, Hesham M. Amin, Ahmed Omar Kaseb
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 4, Pp 255-262 (2024)
Introduction: Galectin-3 plays critical roles in the adhesion, proliferation, and differentiation of tumor cells. Recent data have suggested that galectin-3 plays a role in the development of hepatocellular carcinoma (HCC); however, its prognostic va
Externí odkaz:
https://doaj.org/article/c7007e3fd8d74d43a19828dfc72d4de2
Autor:
Prashant Dogra, Vrushaly Shinglot, Javier Ruiz-Ramírez, Joseph Cave, Joseph D. Butner, Carmine Schiavone, Dan G. Duda, Ahmed O. Kaseb, Caroline Chung, Eugene J. Koay, Vittorio Cristini, Bulent Ozpolat, George A. Calin, Zhihui Wang
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-19 (2024)
Abstract Background Elevated microRNA-155 (miR-155) expression in non-small-cell lung cancer (NSCLC) promotes cisplatin resistance and negatively impacts treatment outcomes. However, miR-155 can also boost anti-tumor immunity by suppressing PD-L1 exp
Externí odkaz:
https://doaj.org/article/f5c916f279b74e3c88a10c02785cb0e7
Autor:
Eleni Gkika, Elke Firat, Sonja Adebahr, Erika Graf, Ilinca Popp, Gianluca Radicioni, Simon S. Lo, Ursula Nestle, Nils H. Nicolay, Gabriele Niedermann, Dan G. Duda, Anca-L. Grosu
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-6 (2023)
Abstract We performed a prospective study of circulating immune cell changes after stereotactic body radiotherapy (SBRT) in 50 early-stage NSCLC patients. We found no significant increase in CD8+ cytotoxic T lymphocytes at first follow-up (the primar
Externí odkaz:
https://doaj.org/article/537504b77a584db7a48979724411a17a
Autor:
Nina M. Muñoz, Crystal Dupuis, Malea Williams, Katherine Dixon, Amanda McWatters, Jie Zhang, Swathi Pavuluri, Arvind Rao, Dan G. Duda, Ahmed Kaseb, Rahul A. Sheth
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Immunotherapy is a promising new treatment approach for hepatocellular carcinoma (HCC), but there are numerous barriers to immunotherapy in HCC, including an immunosuppressive microenvironment and the “immunotolerance” of the liver. Hype
Externí odkaz:
https://doaj.org/article/6e56596188e0454099cea70865ddd04f
Autor:
Joan How, Siyang Ren, Jennifer Lombardi‐Story, Meghan Bergeron, Julia Foster, Phillip C. Amrein, Andrew M. Brunner, Amir T. Fathi, Hanno Hock, Anna Khachatryan, Hiroto Kikuchi, Mei Rosa Ng, Jenna Moran, Rupa Narayan, Donna Neuberg, Aura Ramos, Tina Som, Meghan Vartanian, Yi‐Bin Chen, Dan G. Duda, Gabriela S. Hobbs
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 434-442 (2022)
Abstract We conducted a single‐center, open‐label, dose escalation, and expansion phase I trial of the antiangiogenic multikinase inhibitor regorafenib in patients with advanced myeloid neoplasms. We enrolled 16 patients with relapsed/refractory
Externí odkaz:
https://doaj.org/article/b768134a01424428b03dc52b7afb2c56
Autor:
Zhangya Pu, Dan G. Duda, Yuanyuan Zhu, Siya Pei, Xiaofang Wang, Yan Huang, Panpan Yi, Zebing Huang, Fang Peng, Xingwang Hu, Xuegong Fan
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-19 (2022)
Abstract Background Hepatocellular carcinoma (HCC) is the most common pathological type of liver cancer. Valosin-containing protein (VCP) is a member of the AAA-ATPase family associated with multiple molecular functions and involved in tumor metastas
Externí odkaz:
https://doaj.org/article/2013d74392a0476dada4eafd63451ed6
Autor:
Yuling Xiao, Jiang Chen, Hui Zhou, Xiaodong Zeng, Zhiping Ruan, Zhangya Pu, Xingya Jiang, Aya Matsui, Lingling Zhu, Zohreh Amoozgar, Dean Shuailin Chen, Xiangfei Han, Dan G. Duda, Jinjun Shi
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
The p53 tumor suppressor gene is frequently mutated in liver cancer. Here the authors show that restoration of p53 expression with a mRNA nanoparticle platform elicits anti-tumor immune responses and promotes response to immune checkpoint blockade in
Externí odkaz:
https://doaj.org/article/8660efc1328e4024abac3ad797dc13bf
Autor:
Romualdo Barroso-Sousa, Tanya E. Keenan, Tianyu Li, Nabihah Tayob, Lorenzo Trippa, Ricardo G. Pastorello, Edward T. Richardson III, Deborah Dillon, Zohreh Amoozgar, Beth Overmoyer, Stuart J. Schnitt, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer Van Allen, Dan G. Duda, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract This single-arm phase II study investigated the efficacy and safety of cabozantinib combined with nivolumab in metastatic triple-negative breast cancer (mTNBC). The primary endpoint was objective response rate (ORR) by RECIST 1.1. Biopsies a
Externí odkaz:
https://doaj.org/article/1588be2699b0434ab5c7f6e1a6080ecb
Autor:
Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-6 (2021)
Abstract A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings
Externí odkaz:
https://doaj.org/article/2d357221a247457589d886c5e06e1e3d
Autor:
Wende Li, Sen Li, Ivy X. Chen, Yujiao Liu, Rakesh R. Ramjiawan, Chi-Ho Leung, Leo E. Gerweck, Dai Fukumura, Jay S. Loeffler, Rakesh K. Jain, Dan G. Duda, Peigen Huang
Publikováno v:
Radiation Oncology, Vol 16, Iss 1, Pp 1-12 (2021)
Abstract Background Patients with metastatic HER2/neu-positive (HER2/neu +) breast cancer (BC) often experience treatment resistance, disease recurrences and metastases. Thus, new approaches for improving the treatment of HER2/neu + BC to prevent met
Externí odkaz:
https://doaj.org/article/72ed3803e97d40d080480ecd872ff483